​

Funding Round

Series C - Silverback Therapeutics

Series C - Silverback Therapeutics

Investment Firm

Overview

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.

Announced Date

Sep 23, 2020

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

EcoR1 Capital

EcoR1 Capital

EcoR1 Capital is a early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

10

Investor Name
Participant InvestorOrbiMed
Participant InvestorPontifax
Participant InvestorFrazier Healthcare Partners
Participant InvestorFidelity
Participant InvestorU.S. Venture Partners

Round Details and Background

Silverback Therapeutics raised $85000000 on 2020-09-23 in Series C

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 11, 2020
Series B - Silverback Therapeutics
9-78.5M
Sep 23, 2020
Series C - Silverback Therapeutics
10-85.0M
Oct 01, 2019
Convertible Note - Silverback Therapeutics
1-10.0M
Feb 14, 2017
Series A - Silverback Therapeutics
-10.0M

Recent Activity

There is no recent news or activity for this profile.